Teva Historical Balance Sheet

TEVA Stock

USD 15.12 0.37 2.39%

Trend analysis of Teva Pharma Industries balance sheet accounts such as Total Stockholder Equity of 9.8 B, Property Plant And Equipment Net of 3.3 B, Net Debt of 8.3 B or Cash of 3.5 B provides information on Teva Pharma's total assets, liabilities, and equity, which is the actual value of Teva Pharma Industries to its prevalent stockholders. By breaking down trends over time using Teva Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Teva Pharma Industries latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Teva Pharma Industries is a good buy for the upcoming year.

Teva Pharma Inventory

2.38 Billion

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

About Teva Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Teva Pharma Industries at a specified time, usually calculated after every quarter, six months, or one year. Teva Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Teva Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Teva currently owns. An asset can also be divided into two categories, current and non-current.

Teva Pharma Balance Sheet Chart

At present, Teva Pharma's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 9.8 B, whereas Total Assets are forecasted to decline to about 26.8 B.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Teva Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Teva Pharma Industries books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Teva Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Teva Pharma Industries are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Teva Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	21.6B	20.2B	18.1B	9.6B
Total Assets	44.0B	43.5B	39.3B	26.8B

Short Long Term Debt Total Total Assets

Teva Pharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Common Stock	Other Liab
Total Assets		0.82	0.19	0.95	0.71	0.91	0.78	0.3	0.0	0.99	0.53	0.0	0.93	0.55	0.76	0.81	-0.13	0.36	0.83	0.84	0.71	0.92	0.14	-0.17	-0.66	0.54
Short Long Term Debt Total	0.82		0.31	0.79	0.19	0.75	0.99	-0.24	-0.2	0.86	0.01	-0.2	0.65	0.74	0.96	0.58	-0.12	0.66	0.94	0.52	0.61	0.84	-0.34	0.26	-0.44	0.7
Other Current Liab	0.19	0.31		0.16	-0.09	0.11	0.31	-0.37	0.07	0.22	-0.19	0.07	-0.04	0.41	0.45	-0.01	0.72	0.56	0.43	0.05	0.17	0.13	-0.38	0.43	-0.25	0.63
Total Current Liabilities	0.95	0.79	0.16		0.63	0.94	0.74	0.21	0.07	0.91	0.54	0.07	0.91	0.68	0.71	0.87	0.0	0.42	0.81	0.9	0.78	0.82	0.17	-0.1	-0.78	0.49
Total Stockholder Equity	0.71	0.19	-0.09	0.63		0.62	0.15	0.83	0.17	0.66	0.89	0.17	0.81	-0.03	0.14	0.68	-0.14	-0.22	0.28	0.77	0.48	0.59	0.62	-0.64	-0.53	0.03
Property Plant And Equipment Net	0.91	0.75	0.11	0.94	0.62		0.69	0.21	0.12	0.86	0.57	0.12	0.89	0.72	0.66	0.92	-0.05	0.43	0.75	0.91	0.68	0.72	0.29	-0.04	-0.82	0.38
Net Debt	0.78	0.99	0.31	0.74	0.15	0.69		-0.24	-0.34	0.83	-0.01	-0.34	0.62	0.67	0.95	0.54	-0.15	0.61	0.92	0.42	0.61	0.84	-0.42	0.24	-0.37	0.67
Retained Earnings	0.3	-0.24	-0.37	0.21	0.83	0.21	-0.24		-0.03	0.25	0.81	-0.03	0.47	-0.46	-0.35	0.37	-0.35	-0.72	-0.24	0.41	0.22	0.23	0.65	-0.9	-0.11	-0.45
Cash	0.0	-0.2	0.07	0.07	0.17	0.12	-0.34	-0.03		-0.1	0.09	1.0	-0.04	0.22	-0.11	0.04	0.41	0.27	-0.04	0.38	-0.19	-0.24	0.54	0.21	-0.38	0.17
Non Current Assets Total	0.99	0.86	0.22	0.91	0.66	0.86	0.83	0.25	-0.1		0.46	-0.1	0.89	0.52	0.8	0.75	-0.17	0.37	0.86	0.76	0.69	0.95	0.03	-0.15	-0.58	0.58
Non Currrent Assets Other	0.53	0.01	-0.19	0.54	0.89	0.57	-0.01	0.81	0.09	0.46		0.09	0.72	-0.05	-0.05	0.7	-0.04	-0.3	0.12	0.71	0.43	0.36	0.74	-0.63	-0.61	-0.18
Cash And Short Term Investments	0.0	-0.2	0.07	0.07	0.17	0.12	-0.34	-0.03	1.0	-0.1	0.09		-0.04	0.22	-0.11	0.04	0.41	0.27	-0.04	0.38	-0.19	-0.24	0.54	0.21	-0.38	0.17
Net Receivables	0.93	0.65	-0.04	0.91	0.81	0.89	0.62	0.47	-0.04	0.89	0.72	-0.04		0.41	0.57	0.9	-0.16	0.18	0.68	0.87	0.78	0.85	0.28	-0.33	-0.72	0.27
Common Stock Shares Outstanding	0.55	0.74	0.41	0.68	-0.03	0.72	0.67	-0.46	0.22	0.52	-0.05	0.22	0.41		0.71	0.56	0.31	0.83	0.72	0.57	0.43	0.37	-0.14	0.58	-0.68	0.57
Non Current Liabilities Total	0.76	0.96	0.45	0.71	0.14	0.66	0.95	-0.35	-0.11	0.8	-0.05	-0.11	0.57	0.71		0.47	0.05	0.78	0.98	0.43	0.51	0.8	-0.38	0.39	-0.46	0.85
Inventory	0.81	0.58	-0.01	0.87	0.68	0.92	0.54	0.37	0.04	0.75	0.7	0.04	0.9	0.56	0.47		-0.05	0.23	0.59	0.89	0.77	0.64	0.37	-0.19	-0.83	0.14
Other Current Assets	-0.13	-0.12	0.72	0.0	-0.14	-0.05	-0.15	-0.35	0.41	-0.17	-0.04	0.41	-0.16	0.31	0.05	-0.05		0.46	0.11	0.06	0.04	-0.27	-0.03	0.45	-0.44	0.33
Other Stockholder Equity	0.36	0.66	0.56	0.42	-0.22	0.43	0.61	-0.72	0.27	0.37	-0.3	0.27	0.18	0.83	0.78	0.23	0.46		0.75	0.26	0.21	0.3	-0.36	0.82	-0.51	0.8
Total Liab	0.83	0.94	0.43	0.81	0.28	0.75	0.92	-0.24	-0.04	0.86	0.12	-0.04	0.68	0.72	0.98	0.59	0.11	0.75		0.57	0.6	0.84	-0.25	0.3	-0.6	0.83
Total Current Assets	0.84	0.52	0.05	0.9	0.77	0.91	0.42	0.41	0.38	0.76	0.71	0.38	0.87	0.57	0.43	0.89	0.06	0.26	0.57		0.65	0.61	0.52	-0.21	-0.86	0.27
Short Term Debt	0.71	0.61	0.17	0.78	0.48	0.68	0.61	0.22	-0.19	0.69	0.43	-0.19	0.78	0.43	0.51	0.77	0.04	0.21	0.6	0.65		0.71	-0.08	-0.21	-0.58	0.21
Intangible Assets	0.92	0.84	0.13	0.82	0.59	0.72	0.84	0.23	-0.24	0.95	0.36	-0.24	0.85	0.37	0.8	0.64	-0.27	0.3	0.84	0.61	0.71		-0.13	-0.2	-0.41	0.55
Accounts Payable	0.14	-0.34	-0.38	0.17	0.62	0.29	-0.42	0.65	0.54	0.03	0.74	0.54	0.28	-0.14	-0.38	0.37	-0.03	-0.36	-0.25	0.52	-0.08	-0.13		-0.47	-0.4	-0.33
Short Term Investments	-0.17	0.26	0.43	-0.1	-0.64	-0.04	0.24	-0.9	0.21	-0.15	-0.63	0.21	-0.33	0.58	0.39	-0.19	0.45	0.82	0.3	-0.21	-0.21	-0.2	-0.47		-0.14	0.46
Common Stock	-0.66	-0.44	-0.25	-0.78	-0.53	-0.82	-0.37	-0.11	-0.38	-0.58	-0.61	-0.38	-0.72	-0.68	-0.46	-0.83	-0.44	-0.51	-0.6	-0.86	-0.58	-0.41	-0.4	-0.14		-0.36
Other Liab	0.54	0.7	0.63	0.49	0.03	0.38	0.67	-0.45	0.17	0.58	-0.18	0.17	0.27	0.57	0.85	0.14	0.33	0.8	0.83	0.27	0.21	0.55	-0.33	0.46	-0.36

Click cells to compare fundamentals

Teva Pharma Account Relationship Matchups

Teva Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	50.6B	47.7B	44.0B	43.5B	39.3B	26.8B
Short Long Term Debt Total	26.4B	23.5B	21.6B	20.2B	18.1B	9.6B
Other Current Liab	8.1B	7.8B	7.4B	8.0B	8.8B	9.3B
Total Current Liabilities	13.2B	11.0B	11.5B	12.2B	12.8B	6.7B
Total Stockholder Equity	10.0B	10.3B	7.9B	7.5B	5.4B	9.8B
Property Plant And Equipment Net	6.9B	6.5B	6.2B	6.1B	4.9B	3.3B
Net Debt	24.2B	21.3B	18.8B	16.9B	14.8B	8.3B
Retained Earnings	(10.9B)	(10.5B)	(12.9B)	(13.5B)	(15.2B)	(14.4B)
Cash	2.2B	2.2B	2.8B	3.2B	3.3B	3.5B
Non Current Assets Total	37.6B	35.1B	32.0B	31.0B	26.8B	19.0B
Non Currrent Assets Other	538M	515M	441M	463M	462M	592.2M
Cash And Short Term Investments	2.2B	2.2B	2.8B	3.2B	3.3B	3.5B
Net Receivables	4.6B	4.5B	3.7B	3.4B	3.1B	3.0B
Common Stock Shares Outstanding	1.1B	1.1B	1.1B	1.1B	1.1B	789.0M
Liabilities And Stockholders Equity	50.6B	47.7B	44.0B	43.5B	39.3B	26.8B
Non Current Liabilities Total	26.4B	25.4B	23.8B	23.1B	20.8B	21.9B
Inventory	4.4B	3.8B	3.8B	4.0B	3.0B	2.4B
Other Current Assets	1.8B	2.1B	1.7B	1.8B	3.2B	3.3B
Other Stockholder Equity	23.3B	23.4B	23.6B	23.7B	23.7B	24.9B
Total Liab	39.6B	36.4B	35.3B	35.4B	33.6B	35.3B
Total Current Assets	13.0B	12.6B	12.1B	12.5B	12.6B	7.9B
Short Term Debt	3.3B	1.5B	2.2B	1.7B	1.8B	1.3B
Intangible Assets	8.9B	7.5B	6.3B	5.4B	4.4B	4.7B
Accounts Payable	1.8B	1.7B	1.9B	2.6B	2.2B	2.1B
Accumulated Other Comprehensive Income	(2.4B)	(2.7B)	(2.8B)	(2.7B)	(3.1B)	(3.0B)
Other Liab	3.7B	3.2B	3.4B	4.4B	5.1B	5.3B
Long Term Debt	22.7B	21.6B	19.1B	18.2B	16.0B	12.7B
Property Plant Equipment	6.4B	6.3B	6.0B	6.2B	7.1B	4.8B
Current Deferred Revenue	7.3B	7.0B	1.5B	4.9B	5.7B	3.1B
Good Will	20.6B	20.0B	17.6B	17.2B	15.1B	17.6B
Property Plant And Equipment Gross	6.9B	6.5B	6.2B	11.8B	9.4B	5.9B
Short Long Term Debt	3.2B	1.4B	2.1B	1.7B	1.8B	2.5B
Net Tangible Assets	(22.1B)	(19.5B)	(17.2B)	(16.0B)	(14.4B)	(15.1B)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:

How To Invest In Teva

Details

Is Teva Stock a good investment?

Details

What is Teva Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.4

Earnings Share

(1.43)

Revenue Per Share

14.628

Quarterly Revenue Growth

(0.05)

Return On Assets

0.0509

The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Teva Historical Balance Sheet

Teva Pharma Inventory

2.38 Billion

About Teva Balance Sheet Analysis

Teva Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Teva Pharma balance sheet Correlations

Teva Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Teva Pharma balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.98	Non Current Liabilities Total
Non Current Liabilities Total	+ 0.96	Short Long Term Debt Total
Total Current Liabilities	+ 0.95	Total Assets

Short Term Investments	- 0.9	Retained Earnings
Common Stock	- 0.86	Total Current Assets
Common Stock	- 0.83	Inventory
Common Stock	- 0.82	Property Plant And Equipment Net
Common Stock	- 0.78	Total Current Liabilities
Common Stock	- 0.72	Net Receivables